Skip to navigation Skip to content

Ofatumumab Versus Teriflunomide

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 900
Medication: Ofatumumab Versus Teriflunomide
Location: Texas
Institutions: Clinical Trial Network
7080 southwest fwy, Houston, TX 77074 Contact Information
Michelle Espiritu
281-533-5000
mespiritu@ctntexas.com

Funding:

Novartis

Description

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.

Share